These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5589298)

  • 41. The effects of various doses and various applications of heparin on the fat metabolism and on blood coagulation.
    Losonczy H; Nagy I
    Wien Klin Wochenschr; 1984 Dec; 96(24):885-9. PubMed ID: 6528619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium.
    Berkowitz SD
    Orthopedics; 1995 Jul; 18 Suppl():18-20. PubMed ID: 7479421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Drug therapy of deep venous thrombosis].
    Bounameaux H
    Ther Umsch; 1996 Apr; 53(4):272-6. PubMed ID: 8658349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Casual inference.
    Rothman KJ; Lanes S; Robins J
    Epidemiology; 1993 Nov; 4(6):555-6. PubMed ID: 8268286
    [No Abstract]   [Full Text] [Related]  

  • 45. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring heparin therapy with thromboelastography and activated partial thromboplastin time.
    Lee BY; Taha S; Trainor FS; Kavner D; McCann WJ
    World J Surg; 1980 May; 4(3):323-30. PubMed ID: 7415185
    [No Abstract]   [Full Text] [Related]  

  • 47. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of heparin, low molecular weight (LMW) heparin, and a heparin analogue on experimental venous thrombosis in the rabbit.
    Björck CG; Bergqvist D; Esquivel C; Nilsson B; Rudsvik Y
    Acta Chir Scand; 1984; 150(8):629-33. PubMed ID: 6085202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of experimental ileus on blood coagulability of peripheral venous and portal blood in dogs.
    Tolloczko A; Niewiarowski S; Myśliwiec M
    Pol Med J; 1969; 8(1):144-50. PubMed ID: 5782154
    [No Abstract]   [Full Text] [Related]  

  • 50. Ultrapore filter-induced thrombocytopenia.
    Gervin AS; Mason K; Limbird T; Silver D
    Surgery; 1974 Apr; 75(4):566-72. PubMed ID: 4840803
    [No Abstract]   [Full Text] [Related]  

  • 51. Letter: Decreased sensitivity to oral anticoagulant therapy after attacks of migraine.
    Narasimhan P
    Lancet; 1974 Nov; 2(7889):1143. PubMed ID: 4139440
    [No Abstract]   [Full Text] [Related]  

  • 52. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
    Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heparin therapy in the haemolytic-uraemic syndrome.
    Gilchrist GS; Lieberman E; Ekert H; Fine RN; Grushkin C
    Lancet; 1969 Jun; 1(7606):1123-6. PubMed ID: 4181603
    [No Abstract]   [Full Text] [Related]  

  • 54. [Significance of disordered antithrombin III function in disseminated intravascular coagulation and deep venous thrombosis for anticoagulant therapy].
    von Blohn G; Reiter B; Hellstern P; Wenzel E; Köhler M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):426-38. PubMed ID: 6083907
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Use of heparin in the early post-traumatic period in burns and hemorrhage].
    Kil'diushov AN
    Anesteziol Reanimatol; 1994; (5):26-8. PubMed ID: 7893070
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood coagulation studies and extracorporeal circulation in man.
    Thurnherr N
    Thromb Diath Haemorrh; 1967 Dec; 18(3-4):634-46. PubMed ID: 5590250
    [No Abstract]   [Full Text] [Related]  

  • 57. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE; Meriwether E
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 59. Intraoperative single-dose heparin prophylaxis against deep-vein thrombosis.
    Jones DP; Byrne P; Mackenzie R; Ameli FM; Provan JL
    Can J Surg; 1984 Jan; 27(1):15-6. PubMed ID: 6380692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Thrombolytic action of heparin and a low molecular weight fraction].
    Bousquet F; Doutremepuich C; Gestreau JL; Masse A; Toulemonde F; Vairel EG
    Therapie; 1985; 40(1):13-6. PubMed ID: 4002178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.